We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Antiviral Drugs for Gaucher’s Disease Appears to Inhibit Growth of SARS CoV-2

By HospiMedica International staff writers
Posted on 28 May 2020
Print article
Illustration
Illustration
A team of researchers from Israel have found two antiviral drugs that are used to treat a genetic disorder known as Gaucher’s disease to be effective against the coronavirus.

One of these drugs, Cerdelga, has already been approved for use by the US Food and Drug Administration while the second drug — Venglustat — is close to completing the approval process, with both the drugs likely to be fast-tracked for use on COVID-19 patients in Israel.

The Israel Institute for Biological Research {(IIBR) Ness Ziona, Israel} has published the results of their study of the treatment on mice and proposed an antiviral treatment for COVID-19 in which the two drugs should be taken together. In their study, the researchers found that a combination of the two antiviral drugs for Gaucher’s disease appeared to inhibit the growth of SARS CoV-2 and could also prove effective against other virus infections. Their test of an analog of Cerdelga and Venglustat revealed that a combination of the drugs significantly reduced the replication capacity of the coronavirus and destruction of the infected cells.

The researchers who tested the antiviral drugs on mouse models using four different RNA viruses found the two drugs to be effective in all four cases. In their study published in bioRxiv, the researchers have noted that the drugs “have an antiviral effect on the SARS-CoV-2 clinical isolate in vitro, with a single dose able to significantly inhibit viral replication within 24–48 h” in the case of COVID-19. The researchers are now testing both the drugs for their effectiveness in treating animals infected with the coronavirus.


Related Links:
Israel Institute for Biological Research (IIBR)

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Digital Radiography Generator
meX+20BT lite

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.